XML 30 R14.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Revenue Recognition and Accounts Receivable | 12 Months Ended
--- | ---
Dec. 31, 2021
Revenue from Contract with Customer [Abstract] |
Revenue Recognition and Accounts Receivable | Revenue Recognition and Accounts Receivable The following table presents the Company’s net sales by product category for each of our reportable segments for the years ended December 31, 2021, 2020, and 2019, respectively:
(In millions) | 2021 Net Sales
Product Category | Developed Markets |  | Greater China |  | JANZ |  | Emerging Markets |  | Total
Brands | 5,759.2 |  |  | 2,207.8 |  |  | 1,197.1 |  |  | 1,677.2 |  |  | 10,841.3 |
Complex Gx and Biosimilars | 1,241.6 |  |  | 0.2 |  |  | 46.5 |  |  | 53.8 |  |  | 1,342.1 |
Generics | 3,427.9 |  |  | 4.8 |  |  | 783.8 |  |  | 1,413.7 |  |  | 5,630.2 |
Total Viatris | $ | 10,428.7 |  |  | $ | 2,212.8 |  |  | $ | 2,027.4 |  |  | $ | 3,144.7 |  |  | $ | 17,813.6 |
(In millions) | 2020 Net Sales
Product Category | Developed Markets |  | Greater China |  | JANZ |  | Emerging Markets |  | Total
Brands | 3,920.7 |  |  | 253.9 |  |  | 617.0 |  |  | 443.3 |  |  | 5,234.9 |
Complex Gx and Biosimilars | 1,202.6 |  |  | 0.7 |  |  | 42.8 |  |  | 49.4 |  |  | 1,295.5 |
Generics | 3,387.6 |  |  | 5.3 |  |  | 535.5 |  |  | 1,361.1 |  |  | 5,289.5 |
Total Viatris | $ | 8,510.9 |  |  | $ | 259.9 |  |  | $ | 1,195.3 |  |  | $ | 1,853.8 |  |  | $ | 11,819.9 |
(In millions) | 2019 Net Sales
Product Category | Developed Markets |  | Greater China |  | JANZ |  | Emerging Markets |  | Total
Brands | 4,199.1 |  |  | 207.6 |  |  | 533.3 |  |  | 422.1 |  |  | 5,362.1 |
Complex Gx and Biosimilars | 1,127.4 |  |  | 0.4 |  |  | 23.8 |  |  | 59.7 |  |  | 1,211.3 |
Generics | 2,913.5 |  |  | 6.6 |  |  | 635.4 |  |  | 1,241.4 |  |  | 4,796.9 |
Total Viatris | $ | 8,240.0 |  |  | $ | 214.6 |  |  | $ | 1,192.5 |  |  | $ | 1,723.2 |  |  | $ | 11,370.3 |
The following table presents net sales on a consolidated basis for select key products for the year ended December 31, 2021:
(In millions) |  |  |  | Year Ended December 31, 2021
Select Key Global Products |  |  |  |
Lipitor ® |  |  |  | $ | 1,663.2 |
Norvasc ® |  |  |  | 824.7 |
Lyrica ® |  |  |  | 728.5 |
Viagra ® |  |  |  | 533.8 |
EpiPen® Auto-Injectors |  |  |  | 391.7 |
Celebrex ® |  |  |  | 344.4 |
Effexor ® |  |  |  | 316.8 |
Creon ® |  |  |  | 309.8 |
Zoloft ® |  |  |  | 284.3 |
Xalabrands |  |  |  | 226.0 |
Select Key Segment Products |  |  |  |
Influvac ® |  |  |  | $ | 299.3 |
Amitiza ® |  |  |  | 201.5 |
Xanax ® |  |  |  | 185.9 |
Dymista ® |  |  |  | 168.0 |
Yupelri ® |  |  |  | 161.9 |
____________ (a)The Company does not disclose net sales for any products considered competitively sensitive. (b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches. (c)Prior periods are not presented due to significance of products acquired as part of the Combination. Variable Consideration and Accounts Receivable The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the years ended December 31, 2021, 2020 and 2019, respectively:
| Year Ended December 31,
(In millions) | 2021 |  | 2020 |  | 2019
Gross sales | $ | 30,553.4 |  |  | $ | 19,899.1 |  |  | $ | 19,012.2 |
Gross to net adjustments: |  |  |  |  |
Chargebacks | (5,530.1) |  |  | (3,656.2) |  |  | (3,309.6) |
Rebates, promotional programs and other sales allowances | (6,135.6) |  |  | (3,765.5) |  |  | (3,629.3) |
Returns | (384.6) |  |  | (329.7) |  |  | (237.9) |
Governmental rebate programs | (689.5) |  |  | (327.8) |  |  | (465.1) |
Total gross to net adjustments | $ | (12,739.8) |  |  | $ | (8,079.2) |  |  | $ | (7,641.9) |
Net sales | $ | 17,813.6 |  |  | $ | 11,819.9 |  |  | $ | 11,370.3 |
The following is a rollforward of the categories of variable consideration during 2021:
(In millions) | Balance at December 31, 2020 |  | Current Provision Related to Sales Made in the Current Period |  | Measurement Period Adjustments and Reclasses |  | Checks/ Credits Issued to Third Parties |  | Effects of Foreign Exchange |  | Balance at December 31, 2021
Chargebacks | $ | 585.2 |  |  | $ | 5,530.1 |  |  | $ | 63.4 |  |  | $ | (5,585.4) |  |  | $ | (1.6) |  |  | $ | 591.7 |
Rebates, promotional programs and other sales allowances | 1,576.3 |  |  | 6,135.6 |  |  | (57.6) |  |  | (6,267.1) |  |  | (14.2) |  |  | 1,373.0 |
Returns | 539.9 |  |  | 384.6 |  |  | 269.0 |  |  | (499.0) |  |  | (7.7) |  |  | 686.8 |
Governmental rebate programs | 313.3 |  |  | 689.5 |  |  | 110.6 |  |  | (705.2) |  |  | (9.0) |  |  | 399.2 |
Total | $ | 3,014.7 |  |  | $ | 12,739.8 |  |  | $ | 385.4 |  |  | $ | (13,056.7) |  |  | $ | (32.5) |  |  | $ | 3,050.7 |
Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net revenues and as a contra-asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2021 and 2020, respectively:
(In millions) | December 31, 2021 |  | December 31, 2020
Accounts receivable, net | $ | 1,688.6 |  |  | $ | 1,802.9 |
Other current liabilities | 1,362.1 |  |  | 1,211.8 |
Total | $ | 3,050.7 |  |  | $ | 3,014.7 |
We have not made and do not anticipate making any significant changes to the methodologies that we use to measure provisions for variable consideration; however, the balances within these reserves can fluctuate significantly through the consistent application of our methodologies. Historically, we have not recorded in any current period any material amounts related to adjustments made to prior period reserves.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration